RecruitingNot ApplicableNCT06972719
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
Patient Centered Education About Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy: a Pilot Randomized Controlled Trial
Sponsor
Duke University
Enrollment
50 participants
Start Date
Sep 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
Eligibility
Sex: FEMALEMin Age: 19 YearsMax Age: 50 Years
Inclusion Criteria3
- BRCA1 or BRCA2 germline mutation
- scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist
- premenopausal
Exclusion Criteria4
- personal history of cancer
- postmenopausal
- >50 years old
- unable to provide informed consent in English
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALExperimental Arm
Participants will be randomized to SOC plus the video.
BEHAVIORALSOC Arm
Participants will be randomized to SOC counseling.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06972719
Related Trials
Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NCT068176941 location
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT0639551914 locations
Combination Therapy in Cancers With Mutations in DNA Repair Genes
NCT056947151 location
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
NCT061771711 location
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT041500422 locations